uploads/2016/02/ANR18.png

What Are Analysts’ Recommendations for LifePoint and Its Peers?

By

Updated

Update on analyst recommendations

LifePoint Health (LPNT) released its earnings for 4Q15 and 2015 on February 12, 2016. Following the earnings release, analysts revised their recommendations for the company.

According to a Bloomberg consensus of 23 brokerage companies on February 12, 2016, 34.8% rated LifePoint as a “buy,” while 60.9% rated the company as a “hold.” 4.3% of brokerage companies recommended that the stock be sold.

The table above demonstrates 18 brokerage companies and their estimated target prices for LifePoint. The consensus 12-month target price for the company is $80.8. This translates to a potential return of ~33.7% compared to LifePoint’s closing price of $60.5 on February 16, 2016.

Article continues below advertisement

Analysts’ recommendations for LifePoint’s peers

As per a Bloomberg consensus of 19 brokerage companies on February 5, 2016, 63.2% rated Universal Health Service (UHS) as a “buy,” while 31.6% rated it as a “hold.” 5.3% recommended that the stock be sold.

According to a Bloomberg consensus of 26 broker companies on January 29, 2016, 68.0% recommended HCA Holdings (HCA) as a “buy,” while 32.0% rated the company as a “hold.” None rated the company as a “sell.”

According to the consensus of 25 brokerage companies on February 16, 2016, 24.0% recommended Community Health Systems (CYH) as a “buy,” while 72.0% rated the company as a “hold.” 4% of brokerage houses recommended that the company be sold.

To avoid excessive company-specific risks, investors could choose to invest in the iShares Russell 1000 Value ETF (IWD). LifePoint accounts for 0.03% of its total holdings.

Advertisement

More From Market Realist